Preclinical results from OnZurf probe will be presented at clinical congresses
Surgeon Oscar Åkesson Skåne University Hospital, Lund will present “Surface microdialysis (OnZurf Probe) a method for monitoring small bowel ischemia” at “Kirurgveckan” in Malmö and “Surface microdialysis (OnZurf probe) of the gastric tube reconstruction - an experimental study” at the congress “The International Society for Diseases of the Esophagus” in Singapore. The two studies have been performed at Umeå University as a collaboration project between Umeå University, University Hospital of Umeå and Skåne University Hospital.
Continuous monitoring of lactate in patients undergoing surgery may provide the opportunity to detect early leakages. The clinical market seeks systems that allow continuous monitoring of biomarkers in blood and tissue to rapidly detect post-operative complications and to control interventions. In Sweden e.g. many cancer operations are annually conducted where effective monitoring systems are much needed in order to reduce the number of painful and care-consuming complications that increase the cost of treatment.
Senzime have developed user-friendly products for continuous monitoring of glucose and lactate in fluids such as blood and cell cultures. These measurements are important —and often critical—for patients who have undergone surgery and who are at risk for unnecessary and treat-demanding complications such as ischemia (lack of oxygen) and anastomotic leakage (bowel contents leaking into the abdominal cavity). Senzime’s product OnZurf probe makes it possible to carry out continuous biochemical test sampling on specific organs. A clinical study with OnZurf probe is ongoing at Skåne University Hospital at patients who undergone surgery for esophageal cancer (esophageal resection), a procedure carried out on a half-million patients worldwide every year.
OnZurf probe, a new generation of microdialysis catheters that allow for organ specific monitoring of, for example, bowel, liver and heart after surgery. Microdialysis is a technology that was originally developed at the Karolinska Institute in the 1970’s and is today validated in over 15,000 scientific studies.
For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46 708-16 39 12, email: email@example.com
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com